Cargando…
Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
Molecular targeting therapies often cause characteristic adverse effects, such as skin rash during anti-epidermal growth factor receptor (EGFR) therapies, making treatment continuation difficult. In contrast, skin symptoms induced by EGFR inhibition are strongly correlated with the overall survival...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958386/ https://www.ncbi.nlm.nih.gov/pubmed/31703435 http://dx.doi.org/10.3390/ph12040165 |
_version_ | 1783487401726836736 |
---|---|
author | Nishiya, Naoyuki Murai, Moeka Hosoda, Ayumi Yonezawa, Honami Omori, Norikazu |
author_facet | Nishiya, Naoyuki Murai, Moeka Hosoda, Ayumi Yonezawa, Honami Omori, Norikazu |
author_sort | Nishiya, Naoyuki |
collection | PubMed |
description | Molecular targeting therapies often cause characteristic adverse effects, such as skin rash during anti-epidermal growth factor receptor (EGFR) therapies, making treatment continuation difficult. In contrast, skin symptoms induced by EGFR inhibition are strongly correlated with the overall survival of the therapies. Therefore, controlling adverse effects not only facilitates treatment continuation but also increases clinical benefits. In this study, we proposed a novel strategy for reducing EGFR–tyrosine kinase inhibitor (TKI)-induced adverse effects in nontumorous organs by repositioning approved medicines using a zebrafish model. We developed a model system for evaluating chemical quenchers of afatinib, a clinically available irreversible EGFR-TKI, by scoring the inhibition of afatinib-induced hyperformation of lateral line neuromasts in zebrafish larvae. Bucillamine, an antirheumatic drug, was identified as an afatinib quencher in the zebrafish system and inhibited TKI activity in vitro. In addition, bucillamine restored EGFR autophosphorylation and downstream signaling in afatinib-treated A431 cells. Thus, topical bucillamine is a potential reliever of irreversible EGFR-TKI-induced skin rash. The zebrafish model can be applied to a screening for quenchers of other anti-EGFR-targeting therapies, including reversible TKIs and biologics. |
format | Online Article Text |
id | pubmed-6958386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69583862020-01-23 Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling Nishiya, Naoyuki Murai, Moeka Hosoda, Ayumi Yonezawa, Honami Omori, Norikazu Pharmaceuticals (Basel) Article Molecular targeting therapies often cause characteristic adverse effects, such as skin rash during anti-epidermal growth factor receptor (EGFR) therapies, making treatment continuation difficult. In contrast, skin symptoms induced by EGFR inhibition are strongly correlated with the overall survival of the therapies. Therefore, controlling adverse effects not only facilitates treatment continuation but also increases clinical benefits. In this study, we proposed a novel strategy for reducing EGFR–tyrosine kinase inhibitor (TKI)-induced adverse effects in nontumorous organs by repositioning approved medicines using a zebrafish model. We developed a model system for evaluating chemical quenchers of afatinib, a clinically available irreversible EGFR-TKI, by scoring the inhibition of afatinib-induced hyperformation of lateral line neuromasts in zebrafish larvae. Bucillamine, an antirheumatic drug, was identified as an afatinib quencher in the zebrafish system and inhibited TKI activity in vitro. In addition, bucillamine restored EGFR autophosphorylation and downstream signaling in afatinib-treated A431 cells. Thus, topical bucillamine is a potential reliever of irreversible EGFR-TKI-induced skin rash. The zebrafish model can be applied to a screening for quenchers of other anti-EGFR-targeting therapies, including reversible TKIs and biologics. MDPI 2019-11-07 /pmc/articles/PMC6958386/ /pubmed/31703435 http://dx.doi.org/10.3390/ph12040165 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nishiya, Naoyuki Murai, Moeka Hosoda, Ayumi Yonezawa, Honami Omori, Norikazu Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling |
title | Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling |
title_full | Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling |
title_fullStr | Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling |
title_full_unstemmed | Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling |
title_short | Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling |
title_sort | bucillamine prevents afatinib-mediated inhibition of epidermal growth factor receptor signaling |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958386/ https://www.ncbi.nlm.nih.gov/pubmed/31703435 http://dx.doi.org/10.3390/ph12040165 |
work_keys_str_mv | AT nishiyanaoyuki bucillaminepreventsafatinibmediatedinhibitionofepidermalgrowthfactorreceptorsignaling AT muraimoeka bucillaminepreventsafatinibmediatedinhibitionofepidermalgrowthfactorreceptorsignaling AT hosodaayumi bucillaminepreventsafatinibmediatedinhibitionofepidermalgrowthfactorreceptorsignaling AT yonezawahonami bucillaminepreventsafatinibmediatedinhibitionofepidermalgrowthfactorreceptorsignaling AT omorinorikazu bucillaminepreventsafatinibmediatedinhibitionofepidermalgrowthfactorreceptorsignaling |